Celltrion's Truxima Becomes First Rituximab Biosimilar to Obtain Interchangeability Status in the U.S.
Official Recognition for Interchangeable Prescriptions with the Original Drug
No. 1 Prescribed Rituximab Product in the U.S.
Celltrion announced on July 1 that its blood cancer treatment ‘Truxima’ (ingredient name: rituximab) has obtained interchangeability status from the U.S. Food and Drug Administration (FDA). Truxima is the first rituximab biosimilar to acquire interchangeability status in the United States, and as a result, Celltrion has secured exclusivity rights associated with this status.
Truxima, a blood cancer therapy developed by Celltrion, is currently approved in the U.S. for all adult indications held by the original reference drug, including non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and microscopic polyangiitis (MPA).
Interchangeability status is a designation that recognizes the ability to substitute a biosimilar for the original drug. With this approval, Truxima is now officially recognized as clinically equivalent in terms of efficacy and safety when used interchangeably with the original product, providing a stronger foundation for prescription decisions. This is expected to not only increase U.S. healthcare professionals’ confidence in prescribing Truxima, but also significantly improve patient access to treatment and help alleviate healthcare costs in the future.
Furthermore, Truxima’s competitive edge is expected to continue despite recent regulatory changes surrounding biosimilars in the U.S. Regardless of any changes to the system, Truxima remains the only rituximab biosimilar recognized by the FDA as interchangeable with the original drug, which is anticipated to further enhance local practitioners’ trust in prescribing it and solidify its differentiated competitiveness in the market.
Already enjoying high brand recognition and prescription rates in the U.S., Truxima is expected to further strengthen its credibility and market dominance with the acquisition of this status. According to pharmaceutical market research firm IQVIA, as of February this year, Truxima held a 35.8% prescription volume market share in the U.S., ranking first. This achievement, made in competition with global big pharma products including the original reference drug since entering the U.S. market, marks the first time a Korean biosimilar product has reached the number one market share in the United States.
Actual sales results are also robust. Truxima recorded sales of over 300 billion won in North America, including the U.S., last year, achieving more than 40% year-on-year growth and establishing itself as one of Celltrion’s core revenue sources.
Celltrion plans to use Truxima’s interchangeability designation as a momentum to further bolster its competitiveness in the U.S. rituximab market and to solidify the presence of its subsequent oncology biosimilar portfolio.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion spokesperson stated, “Truxima has already proven its product competitiveness by ranking first in prescriptions in the U.S. rituximab market, and with the acquisition of interchangeability status, it has secured a unique position,” adding, “Even amid the evolving regulatory trends in the U.S., we will do our utmost to expand patient access to treatment and alleviate healthcare costs, based on already validated clinical data and prescription evidence.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.